Sue Farrington is Chief Executive of Scleroderma & Raynaud’s UK (SRUK) and President of the Federation of European Scleroderma Associations (FESCA). Sue is Co-Chair of the Rare Auto-Immune Rheumatic Disease Alliance (RAIRDA), a partnership established in 2016 to improve the quality of life of people living with rare autoimmune rheumatic diseases. Since 2013, Sue has been Chair of the Patient Information Forum, an organisation for people working in consumer health information – championing the role that quality information plays in the delivery of positive health outcomes. She is a member of the Rare Disease Forum and chair of an Independent Advisory Group reporting into the DHSC on the development of Quality Standard for rare diseases.

Dr. Sarah Cross is the Vice President and Global Head of Medical Affairs at Premier Research. Dr. Cross received her PhD from UCLA and has previously served in leadership roles in medical affairs and clinical development at CRO, biotech/medtech, and pharmaceutical organizations.

She is responsible for oversight of medical strategy and execution for all phase of clinical trials, and is the external engagement lead responsible for partnerships with patient advocacy groups and professional societies implementing initiatives designed to remove patient barriers, improve diversity and inclusion in medical research, and elevate awareness of clinical trials.

Paul has deep experience in all phases of clinical research across a wide range of indications. He is an expert in the development of site and patient recruitment and retention programs that consider study design and objectives in creating engagement and outreach plans.

At Parexel, he is responsible for developing and executing recruitment and retention strategies across clinical programs. He provides leadership to the execution team as a representative of the patient voice, collaborating with patient advocacy groups and study feasibility teams to drive enrollment and craft innovative and insightful messaging

Angela Sermiento-Betancourt is the Medical Affairs Manager at myTomorrows. Her clinical background enables her to apply scientific rigor and clinical insight, to assist patients and healthcare practitioners in finding information and discovering preapproval treatments. Driven by kindness and empathy, she strives to make a change within the medical field by supporting patients and their families through their healthcare journey.

Allen S. Yang, MD, PhD, is Chief Medical Officer and leads the Research and Clinical Development teams for Summit Therapeutics.

Prior to joining Summit, Allen was the Chief Medical Officer at Xencor Inc where he led the development of Xencor‘s pipeline of novel engineered proteins in oncology and autoimmune diseases. Before Xencor, Allen was at Jazz Pharmaceuticals PLC where he started as the Therapeutic Head for Hematology / Oncology and rose to Head of Clinical Development and acting CMO. He has also served as VP of Clinical Research at Spectrum Pharmaceuticals, Inc. Allen started his career in industry at Amgen, Inc. where he had several roles of increasing responsibility and worked on romiplostim, blinatumomab and arbepoetin alfa. During his career he has led or been a part of numerous drug approvals including, liposomal cytarabine-daunorubicin, asparaginase erwinia chrysanthemi (recombinant)-rywn, defibrotide, solriamfetol, captisol-enabled melphalan, and blinatumomab.

Allen holds an MD and a PhD in Biochemistry from the University of Southern California and a BA in Molecular Biology and Rhetoric from the University of California, Berkeley. He completed his residency in Internal Medicine at the Harbor-UCLA Medical Center and his Medical Oncology fellowship at the MD Anderson Cancer Center. He was also the Chief Fellow in his final year at MD Anderson. He practiced for several years a­­s an academic oncologist at the University of Southern California seeing patients and running a translational cancer research laboratory. He has been awarded several awards and grants during his academic career including the ASCO Young Investigator Award and the ASCO Career Development Award. He has over 100 peer-reviewed publications during his academic and industry careers.

Andy Collinson is a UK-based atopic dermatitis/visible difference patient advocate with a blog, podcast, and social media presence under the handle "Life with a difference."

Mr Collinson has lived with atopic dermatitis his whole life, something which he previously tried to downplay or ignore as much as possible. However, he recently stepped into advocacy and found this work inspiring and also liberating. He aims to spread awareness and create more empathy for atopic dermatitis, which can be so physically and mentally catastrophic, while also offering support to those living with this condition or other visible differences.

Amanda Simonds joined UCB in January 2021 as Patient Engagement and Policy Lead for Immunology across UK & Ireland, leading on policy and patient engagement across a range of conditions including psoriasis, osteoporosis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondyloarthritis.

In October 2024, Ms Simonds took on her current role, collaborating with clinical development, medical and regulatory teams to bring the patient voice into the UCB pipeline. Her role at UCB has three principal dimensions - continuously exploring how to involve patients at all stages of the drug discovery lifecycle, generating insights to inform and shape trial design and recruitment and building long-term collaborations with patient organisations and the broader patient community..

For over fifteen years, her passion to champion patient advocacy has involved her working in a range of patient engagement, communications and public affairs roles at Amgen, Celgene and Novo Nordisk.

Amelia Hursey joined the Parkinson’s Europe team in Jan 2022 as Research Manager, progressing to Strategic Director from Jan 2025. She has delivered the Parkinson’s Europe’s Research Strategy, embedded a volunteer Steering Groups into the organisation and helped to increase Parkinson’s Europe research reputation. She has also brought new initiatives to the table, such as the Parkinson’s Europe’s Engagement Network, which connects the Parkinson’s community across Europe. Parkinson’s Europe is now a partner member of EUPATI, the Non–Profit coalition to support advancements of Disease Modifying Treatments for Parkinson’s and the Critical Path for Parkinson’s. She co- developed Parkinson’s Europe's new 2025-2028 strategy and is leading its delivery.

She has been working in the field of Neurodegenerative research since 2009, is a Patient Organisations board member with EUPATI and a member of EAN’s Guidance Production Group and is co-author on a number of publications about Parkinson’s and patient engagement.

She worked for NIHR’s DeNDRoN delivering clinical trials 2009-2015 and then at Parkinson’s UK as Research Participation Lead 2015-2022. She was responsible for initiatives to increase research participation for people affected by Parkinson’s, HCP’s and researchers, and created the innovative Parkinson’s UK Take Part Hub and co-produced the Staying Connected toolkit.

Andrea Bastek, Ph.D., is VP of Innovation at Florence Healthcare. Her team's mission is to identify the biggest challenges in clinical trial operations and harness technology to solve them. Prior to Florence, Andrea spent 15 years working in clinical trial operations in the cardiac medical device industry. She holds a Ph.D. in Bioengineering from Georgia Tech as well as a BS and MS in Biomedical Engineering from Tulane University.

Life science healthcare executive with global experience in biotechnology and technology. Meldrum is currently CEO of AdhereTech, a HealthTech company focused on improving medication adherence in clinical trials and real-world settings. Previously, he served as CEO of Reset Pharma, developing psychedelics for mental health disorders, and as Chief Commercial Officer for Otsuka Pharmaceuticals North America, where he delivered revenue growth despite pandemic challenges.

His career includes commercial leadership at Orexo, where he developed the award-winning "Out The Monster" campaign, and 11 years at Novartis Pharma in the US and Switzerland. Before healthcare, Meldrum spent 10 years in technology, building on his Electrical and Electronic degree from Strathclyde University.

Meldrum brings extensive expertise in psychiatry, neuroscience, respiratory, dermatology, and digital health, with demonstrated success across organizations of all sizes. Outside work, he's a certified scotch professional and enthusiastic golfer.